window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Novadip secures €10.4M to advance pivotal Phase 3 trial

    Novadip Biosciences has secured €10.4 million in convertible financing to [...]

    September 21, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Telix to acquire ITM in $1.65BN radiopharmaceutical deal

    Telix has agreed to acquire ITM Isotope Technologies Munich in [...]

    September 21, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Andelyn to manufacture FDA-approved Fayuvi gene therapy for Sanfilippo syndrome

    Andelyn Biosciences is manufacturing Ultragenyx’s newly FDA-approved Fayuvi gene therapy [...]

    September 21, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Ariadne Bio launches with Parkinson’s apathy drug candidate

    Ariadne Bio has launched with funding from The Michael J [...]

    September 18, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    MaaT Pharma to advance Phase 3 trial after EMA rejects MaaT013 application

    MaaT Pharma plans to advance a global Phase 3 trial [...]

    September 18, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Big Picture Bio launches with £2.2M to design cancer drug combinations

    Big Picture Bio has launched with £2.2 million in funding [...]

    September 18, 2026
  • Genomics and sequencing,Research & Development,Therapeutic Areas

    Nabsys EGM detects genomic abnormalities in five-sample leukemia study

    Nabsys’ Electronic Genome Mapping technology detected clinically relevant genomic abnormalities [...]

    September 17, 2026
  • Digital & Data,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Passive cough monitoring linked to worsening asthma symptoms

    Contactless monitoring of nocturnal cough has been linked to worsening [...]

    September 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    NIH funds expanded access programme for Neurizon’s ALS therapy

    A US National Institutes of Health grant will fund an [...]

    September 16, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Sapience Therapeutics gets FDA clearance for ST316 FAP study

    The FDA has cleared Sapience Therapeutics to begin clinical development [...]

    September 16, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cyllene gene therapy for bladder disorder gains FDA RMAT designation
    Categories: Drug Discovery & Development
  • Passive cough monitoring linked to worsening asthma symptoms
    Categories: Digital & Data, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • NIH funds expanded access programme for Neurizon’s ALS therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top